ArticleClinical rheumatology2026
MiR‑365b‑5p and MiR‑3614‑5p are elevated in PBMCs of systemic lupus erythematosus and exhibit potential as complementary diagnostic indicators.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionSystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder lacking ideal early diagnostic biomarkers. This study aimed to identify and validate novel microRNAs (miRNAs) in peripheral blood mononuclear cells (PBMCs) as diagnostic biomarkers for SLE.
methodsThis study comprised a screening stage and a validation stage. We performed high-throughput miRNA sequencing in 3 SLE patients and 3 healthy controls, then validated candidate miRNAs in 39 SLE patients and 40 healthy controls using quantitative real-time polymerase chain reaction (qPCR). Diagnostic performance was assessed using receiver operating characteristic (ROC) curves, and correlations with clinical indicators were analysed.
resultsSeventy-eight differentially expressed miRNAs were identified in SLE. Among them, miR-365b-5p and miR-3614-5p were significantly upregulated in SLE PBMCs (both P<0.001). ROC analysis showed area under the curve (AUC) values of 0.733 and 0.782 for the individual models and 0.805 for the combination. MiR-365b-5p was positively correlated with IgM, while miR-3614-5p was associated with immune cell counts, liver and kidney function, and metabolic parameters. Bioinformatics suggested involvement in immune regulation and the MAPK signaling pathway.
conclusionsmiR-365b-5p and miR-3614-5p are significantly elevated in SLE and have favourable diagnostic value. These two miRNAs may serve as complementary diagnostic biomarkers that could facilitate early detection, differential diagnosis, and the elucidation of immune pathogenesis in SLE. Key Points • MiR‑365b‑5p and miR‑3614‑5p were significantly upregulated in SLE PBMCs. • MiR‑365b‑5p and miR‑3614‑5p may serve as novel diagnostic biomarkers for SLE and contribute to its pathogenesis via immune regulation and the MAPK signaling pathway.
Indexed as
Identifiers
42645715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.